| pubmed-article:20043911 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20043911 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:20043911 | lifeskim:mentions | umls-concept:C0061352 | lld:lifeskim |
| pubmed-article:20043911 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:20043911 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:20043911 | lifeskim:mentions | umls-concept:C1528769 | lld:lifeskim |
| pubmed-article:20043911 | lifeskim:mentions | umls-concept:C0125323 | lld:lifeskim |
| pubmed-article:20043911 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20043911 | pubmed:dateCreated | 2010-2-15 | lld:pubmed |
| pubmed-article:20043911 | pubmed:abstractText | The glucagon receptor antagonist BI-32169, recently isolated from Streptomyces sp., was described as a bicyclic peptide, although its primary structure comprises conserved elements of class I and class II lasso peptides. Tandem mass spectrometric and nuclear magnetic resonance spectroscopic studies revealed that BI-32169 is a lasso-structured peptide constituting the new class III of lasso peptides. The determined lasso fold opens new avenues to improve the promising biological activity of BI-32169. | lld:pubmed |
| pubmed-article:20043911 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20043911 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20043911 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20043911 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20043911 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20043911 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20043911 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20043911 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20043911 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:20043911 | pubmed:issn | 1873-3468 | lld:pubmed |
| pubmed-article:20043911 | pubmed:author | pubmed-author:MarahielMoham... | lld:pubmed |
| pubmed-article:20043911 | pubmed:author | pubmed-author:LinneUweU | lld:pubmed |
| pubmed-article:20043911 | pubmed:author | pubmed-author:XieXiulanX | lld:pubmed |
| pubmed-article:20043911 | pubmed:author | pubmed-author:KnappeThomas... | lld:pubmed |
| pubmed-article:20043911 | pubmed:copyrightInfo | Copyright 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. | lld:pubmed |
| pubmed-article:20043911 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20043911 | pubmed:day | 19 | lld:pubmed |
| pubmed-article:20043911 | pubmed:volume | 584 | lld:pubmed |
| pubmed-article:20043911 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20043911 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20043911 | pubmed:pagination | 785-9 | lld:pubmed |
| pubmed-article:20043911 | pubmed:meshHeading | pubmed-meshheading:20043911... | lld:pubmed |
| pubmed-article:20043911 | pubmed:meshHeading | pubmed-meshheading:20043911... | lld:pubmed |
| pubmed-article:20043911 | pubmed:meshHeading | pubmed-meshheading:20043911... | lld:pubmed |
| pubmed-article:20043911 | pubmed:meshHeading | pubmed-meshheading:20043911... | lld:pubmed |
| pubmed-article:20043911 | pubmed:meshHeading | pubmed-meshheading:20043911... | lld:pubmed |
| pubmed-article:20043911 | pubmed:meshHeading | pubmed-meshheading:20043911... | lld:pubmed |
| pubmed-article:20043911 | pubmed:meshHeading | pubmed-meshheading:20043911... | lld:pubmed |
| pubmed-article:20043911 | pubmed:meshHeading | pubmed-meshheading:20043911... | lld:pubmed |
| pubmed-article:20043911 | pubmed:meshHeading | pubmed-meshheading:20043911... | lld:pubmed |
| pubmed-article:20043911 | pubmed:meshHeading | pubmed-meshheading:20043911... | lld:pubmed |
| pubmed-article:20043911 | pubmed:meshHeading | pubmed-meshheading:20043911... | lld:pubmed |
| pubmed-article:20043911 | pubmed:meshHeading | pubmed-meshheading:20043911... | lld:pubmed |
| pubmed-article:20043911 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20043911 | pubmed:articleTitle | The glucagon receptor antagonist BI-32169 constitutes a new class of lasso peptides. | lld:pubmed |
| pubmed-article:20043911 | pubmed:affiliation | Department of Chemistry/Biochemistry, Philipps-University Marburg, Marburg, Germany. | lld:pubmed |
| pubmed-article:20043911 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20043911 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
